Cargando…
Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
BACKGROUND/AIMS: Angiotensin receptor blockers (ARBs) inhibit activated hepatic stellate cell contraction and are thought to reduce the dynamic portion of intrahepatic resistance. This study compared the effects of combined treatment using the ARB candesartan and propranolol versus propranolol monot...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278069/ https://www.ncbi.nlm.nih.gov/pubmed/25548744 http://dx.doi.org/10.3350/cmh.2014.20.4.376 |
_version_ | 1782350463295815680 |
---|---|
author | Kim, Jae Hyun Kim, Jung Min Cho, Youn Zoo Na, Ji Hoon Kim, Hyun Sik Kim, Hyoun A Kang, Hye Won Baik, Soon Koo Kwon, Sang Ok Cha, Seung Hwan Kim, Young Ju Kim, Moon Young |
author_facet | Kim, Jae Hyun Kim, Jung Min Cho, Youn Zoo Na, Ji Hoon Kim, Hyun Sik Kim, Hyoun A Kang, Hye Won Baik, Soon Koo Kwon, Sang Ok Cha, Seung Hwan Kim, Young Ju Kim, Moon Young |
author_sort | Kim, Jae Hyun |
collection | PubMed |
description | BACKGROUND/AIMS: Angiotensin receptor blockers (ARBs) inhibit activated hepatic stellate cell contraction and are thought to reduce the dynamic portion of intrahepatic resistance. This study compared the effects of combined treatment using the ARB candesartan and propranolol versus propranolol monotherapy on portal pressure in patients with cirrhosis in a prospective, randomized controlled trial. METHODS: Between January 2008 and July 2009, 53 cirrhotic patients with clinically significant portal hypertension were randomized to receive either candesartan and propranolol combination therapy (26 patients) or propranolol monotherapy (27 patients). Before and 3 months after the administration of the planned medication, the hepatic venous pressure gradient (HVPG) was assessed in both groups. The dose of propranolol was subsequently increased from 20 mg bid until the target heart rate was reached, and the candesartan dose was fixed at 8 mg qd. The primary endpoint was the HVPG response rate; patients with an HVPG reduction of >20% of the baseline value or to <12 mmHg were defined as responders. RESULTS: The mean portal pressure declined significantly in both groups, from 16 mmHg (range, 12-28 mmHg) to 13.5 mmHg (range, 6-20 mmHg) in the combination group (P<0.05), and from 17 mmHg (range, 12-27 mmHg) to 14 mmHg (range, 7-25 mmHg) in the propranolol monotherapy group (P<0.05). However, the medication-induced pressure reduction did not differ significantly between the two groups [3.5 mmHg (range, -3-11 mmHg) vs. 3 mmHg (range, -8-10 mmHg), P=0.674]. The response rate (55.6% vs. 61.5%, P=0.435) and the reductions in mean blood pressure or heart rate also did not differ significantly between the combination and monotherapy groups. CONCLUSIONS: The addition of candesartan (an ARB) to propranolol confers no benefit relative to classical propranolol monotherapy for the treatment of portal hypertension, and is thus not recommended. |
format | Online Article Text |
id | pubmed-4278069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | The Korean Association for the Study of the Liver |
record_format | MEDLINE/PubMed |
spelling | pubmed-42780692014-12-29 Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension Kim, Jae Hyun Kim, Jung Min Cho, Youn Zoo Na, Ji Hoon Kim, Hyun Sik Kim, Hyoun A Kang, Hye Won Baik, Soon Koo Kwon, Sang Ok Cha, Seung Hwan Kim, Young Ju Kim, Moon Young Clin Mol Hepatol Original Article BACKGROUND/AIMS: Angiotensin receptor blockers (ARBs) inhibit activated hepatic stellate cell contraction and are thought to reduce the dynamic portion of intrahepatic resistance. This study compared the effects of combined treatment using the ARB candesartan and propranolol versus propranolol monotherapy on portal pressure in patients with cirrhosis in a prospective, randomized controlled trial. METHODS: Between January 2008 and July 2009, 53 cirrhotic patients with clinically significant portal hypertension were randomized to receive either candesartan and propranolol combination therapy (26 patients) or propranolol monotherapy (27 patients). Before and 3 months after the administration of the planned medication, the hepatic venous pressure gradient (HVPG) was assessed in both groups. The dose of propranolol was subsequently increased from 20 mg bid until the target heart rate was reached, and the candesartan dose was fixed at 8 mg qd. The primary endpoint was the HVPG response rate; patients with an HVPG reduction of >20% of the baseline value or to <12 mmHg were defined as responders. RESULTS: The mean portal pressure declined significantly in both groups, from 16 mmHg (range, 12-28 mmHg) to 13.5 mmHg (range, 6-20 mmHg) in the combination group (P<0.05), and from 17 mmHg (range, 12-27 mmHg) to 14 mmHg (range, 7-25 mmHg) in the propranolol monotherapy group (P<0.05). However, the medication-induced pressure reduction did not differ significantly between the two groups [3.5 mmHg (range, -3-11 mmHg) vs. 3 mmHg (range, -8-10 mmHg), P=0.674]. The response rate (55.6% vs. 61.5%, P=0.435) and the reductions in mean blood pressure or heart rate also did not differ significantly between the combination and monotherapy groups. CONCLUSIONS: The addition of candesartan (an ARB) to propranolol confers no benefit relative to classical propranolol monotherapy for the treatment of portal hypertension, and is thus not recommended. The Korean Association for the Study of the Liver 2014-12 2014-12-24 /pmc/articles/PMC4278069/ /pubmed/25548744 http://dx.doi.org/10.3350/cmh.2014.20.4.376 Text en Copyright © 2014 by The Korean Association for the Study of the Liver http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Jae Hyun Kim, Jung Min Cho, Youn Zoo Na, Ji Hoon Kim, Hyun Sik Kim, Hyoun A Kang, Hye Won Baik, Soon Koo Kwon, Sang Ok Cha, Seung Hwan Kim, Young Ju Kim, Moon Young Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension |
title | Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension |
title_full | Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension |
title_fullStr | Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension |
title_full_unstemmed | Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension |
title_short | Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension |
title_sort | effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278069/ https://www.ncbi.nlm.nih.gov/pubmed/25548744 http://dx.doi.org/10.3350/cmh.2014.20.4.376 |
work_keys_str_mv | AT kimjaehyun effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension AT kimjungmin effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension AT choyounzoo effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension AT najihoon effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension AT kimhyunsik effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension AT kimhyouna effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension AT kanghyewon effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension AT baiksoonkoo effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension AT kwonsangok effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension AT chaseunghwan effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension AT kimyoungju effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension AT kimmoonyoung effectsofcandesartanandpropranololcombinationtherapyversuspropranololmonotherapyinreducingportalhypertension |